Serelaxin has been demonstrated to attenuate renal fibrosis and inflammation in cardiorenal disease. In the present study, we tested the hypothesis that serelaxin can prevent the decline in renal function in dilated cardiomyopathy (DCM) by targeting renal fibrosis and inflammation. Male transgenic mice with DCM (n = 16) and their wild-type littermates (WT; n = 20) were administered either vehicle or serelaxin (500 g kg −1 day −1 ; subcutaneous minipumps; 8 weeks). Cardiac function was assessed via echocardiography before and during the eighth week of serelaxin treatment. Renal function and inflammation as well as cardiac and renal fibrosis were assessed at the end of the study. Serelaxin had minimal effect on cardiac function (P ≥ 0.99). Tubulointerstitial and glomerular fibrosis were ∼3-fold greater in vehicle-treated DCM mice compared with vehicle-treated WT mice (P ≤ 0.001). Renal mRNA expression of Tnf and Il1 were ∼4-and ∼3-fold greater, respectively, in vehicle-treated DCM mice compared with vehicle-treated WT mice (P ≤ 0.05). Tubulointerstitial and glomerular fibrosis were 46 and 45% less, respectively, in serelaxin-treated DCM mice than in vehicle-treated DCM mice (P ≤ 0.01). Renal cortical mRNA expression of Tnf and Il1 were 56 and 58% less, respectively, in the former group compared with the latter (P ≤ 0.05). The urinary albumin:creatinine ratio was ∼3-fold greater in vehicle-treated DCM mice compared with vehicle-treated WT mice (P = 0.02). The urinary albumin:creatinine ratio was not significantly different between vehicle-treated DCM mice and serelaxin-treated DCM mice (P = 0.38). These data suggest that serelaxin can attenuate renal fibrosis and inflammation and has the potential to exert renoprotective effects in DCM.
INTRODUCTION
Heart failure (HF) patients often develop secondary renal dysfunction, but the precise mechanism by which HF leads to renal injury remains elusive (Lloyd-Jones et al., 2010; Shah & Greaves, 2010) . This remains a challenge for development of new treatments to rescue renal function in HF (Rajapakse, Nanayakkara, & Kaye, 2015) . Renal dysfunction arising from a primary defect in the heart is termed the cardiorenal syndrome (CRS) type 2 (Shah & Greaves, 2010) , 2017) . This is consistent with previous data indicating that renal inflammation is present in patients with chronic HF and in patients with chronic kidney disease (Colombo et al., 2012) . In this context, there is evidence that serelaxin is effective in reducing renal fibrosis and inflammation (Lekgabe et al., 2005; Wang et al., 2017; Yoshida et al., 2012) . Serelaxin prevented tumour necrosis factor-(TNF ) induced endothelial dysfunction in rat aortic endothelial cells (Dschietzig et al., 2012) and interleukin (IL)-1 induced collagen synthesis in human dermal fibroblasts (Unemori & Amento, 1990) . Serelaxin also reduced renal fibrosis, inflammation, apoptosis and expression of transforming growth factor beta (TGF ) in experimental hypertension (Garber et al., 2001; Lekgabe et al., 2005; Yoshida et al., 2012) . Furthermore, serelaxin has been demonstrated to restore the imbalance between Experimental Physiology. 2018;103:1593-1602.
wileyonlinelibrary.com/journal/ephnitric oxide (NO) and oxidative stress in hypertension, which likely contributes to its renoprotective effects (Sasser, Cunningham, & Baylis, 2014; Yoshida et al., 2012) . In this context, our recent data indicate that oxidative stress drives renal fibrosis, inflammation and reduction of glomerular filtration rate in experimental CRS type 2 (Giam et al., 2017) .
In the present study, we tested the hypothesis that serelaxin restores NO bioavailability and attenuates renal fibrosis and inflammation, thereby preventing the loss of renal function in CRS type 2. To this end, we recently validated a new CRS type 2 mouse model, which mimics many features of CRS type 2 in patients (Giam et al., 2017 ). This mouse model was used in the present study to test the effects of serelaxin in CRS type 2. (Grundy, 2015) .
METHODS

Ethical approval
Mice
Eighteen-week-old male mice with dilated cardiomyopathy (DCM; n = 16; AMREP animal facility, Melbourne, Victoria, Australia) and their wild-type (WT) littermates (n = 20; AMREP animal facility) were used in the present study. All mice were allowed ad libitum access to food and water. This DCM model has been described previously (Yamamoto et al., 2003) . DCM mice overexpress the mammalian sterile-like 20 kinase 1 (Mst1) gene in a cardiac-specific manner, which induces apoptosis in cardiomyocytes (Yamamoto et al., 2003) . By 10 weeks of age, DCM mice display evidence of ventricular dilatation and reduced cardiac contractility (Yamamoto et al., 2003) . The severity of HF progresses with age, and renal injury is present by 18 weeks of age in these mice (Giam et al., 2017) .
Experimental protocol
Cardiac structure and function were assessed by echocardiography in eighteen-week-old mice as previously described (Giam et al., 2016) . Forty-eight hours later, osmotic minipumps (Alzet Model 2004;  0.25 l h −1 ; Alzet Corporation, Cupertino, CA, USA) were implanted subcutaneously in mice to administer either serelaxin (Novartis, Basel, Switzerland; 500 g kg −1 day −1 ; n = 18) or vehicle (20 mM sodium acetate, pH 5.0; n = 18) for a period of 8 weeks. Two minipump implantation surgeries were performed 4 weeks apart in each mouse.
Each minipump delivered serelaxin or vehicle for 4 weeks. Briefly, mice were anaesthetized using isoflurane (4-5% induction, 1.5-2% maintenance) delivered through a mask. A subcutaneous injection of
New Findings
• What is the central question of this study?
The aim was to determine the renoprotective effects of serelaxin in the setting of chronic heart failure.
• What are the main findings and its importance?
Our data indicate that serelaxin can reduce renal fibrosis and inflammation in experimental heart failure. Currently, there are no effective treatments to rescue renal function in heart failure patients, and our data suggest that serelaxin might have the potential to reduce renal fibrosis and inflammation in heart failure.
lignocaine (2-4 mg kg −1 ) and carprofen (5 mg kg −1 ) were administered to provide local anaesthesia and to provide pain relief, respectively. Minipumps were then implanted in mice as previously described by us (Giam et al., 2016) . The depth of anaesthesia was monitored throughout the surgery by checking the response of the animal to pedal reflex. During the final week of treatment with serelaxin or vehicle, echocardiography was repeated. Forty-eight hours later, mice were placed in metabolic cages (Tecniplast, Maggio, Italy) to collect a 24 h urine sample. Twenty-four hours later, mice were anaesthetized with isoflurane (in the same manner described above) to perform cardiac catheterization to measure left ventricular function and aortic blood pressure as previously described (Du et al., 2000) . A blood sample was obtained via cardiac puncture for later analysis of plasma nitrate and nitrite. Mice were then killed by rapid excision of the heart whilst under deep isoflurane anaesthesia.
Heart and kidney tissues were collected for analyses of fibrosis and inflammation.
Assessment of fibrosis by Masson's Trichrome staining
Paraffin sections (4 m thick) of hearts and kidneys were used for the assessment of fibrosis. Sections were stained with Masson's Trichrome for the assessment of cardiac and renal fibrosis (Giam et al., 2016) .
Ten random fields were imaged for each section using the Olympus BH2 microscope (×40 magnification). The extent of fibrosis was quantified with Image Pro-Plus software (Adept Electronic Solutions Pty Ltd; Moorabbin, Victoria, Australia) as previously described (Chu et al., 2011) .
Assessment of renal function
The urinary albumin concentration was measured according to the manufacturer's protocol [mouse albumin ELISA kit (E90-134); Bethyl Laboratories Inc., Montgomery, TX, USA; Yu et al., 2016] . Urinary creatinine concentrations were measured using a CREP2 kit (Roche Diagnostics, Meylan, France) according to an established protocol (Badiou, Dupuy, Descomps, & Cristolead, 2003) . The urinary albumin:creatinine ratio was then calculated and used as a measure of renal function.
TA B L E 1 Mouse primer sequences for qRT-PCR
Gene
Forward primer Reverse primer
Gapdh
GGGGCTCTCTGCTCCTCCCTG ACGGCCAAATCCGTTCACACC
Tnf
ATCGGTCCCCAAGATGA TGGTGGTTTGTGAGTGTGAGG
Il1
CGCTTGAGTCGGCAAAGAAATC GAGAGAGATGGTCAATGGCAGA
Il
TGCCACCTTTTGACAGTGATG ATGTGCTGCTGCGAGATTTG
Il6
TCGTGGAAATGAGAAAAGAGTTGTG TCCAGTTTGGTAGCATCCATCAT
Il10
TAATAAGCTCCAAGACCAAGGTG TCCAGCAGACTCAATACACACT
Col1a1
GATTGAGAACATCCGCAGCC TACTCTCCGCTCTTCCAGTCA
Col3a1
ACACGCAAGGCAATGAGACT AAGCAAACAGGGCCAATGTC
Col4a1
GGCTCTCCGGGTTCAATAGG GCCGATGTCTCCACGACTAC
Pai1
TCTCCAATTACTGGGTGAGTCAG GCAGCCGGAAATGACACAT
sma
GACTACTGCCGAGCGTGAG CCGTCAGGCAGTTCGTAGC
Tgf
GACCGCAACAACGCCATC CACTGCTTCCCGAATGTCTGA
Mmp2
TCACTTTCCTGGGCAACAAGT GCCACGAGGAATAGGCTATATCC
Mmp9
GCCGACTTTTGTGGTCTTCC AGCGGTACAAGTATGCCTCTG
Abbreviations: sma, alpha smooth muscle actin; Col1a1, collagen type I; Col3a1, collagen type III; Col4a1, collagen type IV; Gapdh, glyceraldehyde 3-phosphate dehydrogenase; Il1 , interleukin-1 alpha; Il , interleukin-1 beta; Il6, interleukin-6; Il10, interleukin-10; Mmp2, matrix metalloproteinase-2; Mmp9, matrix metalloproteinase-9; Pai1, plasminogen activator inhibitor-1; Tgf , transforming growth factor beta; and Tnf , tumour necrosis factor alpha.
Renal mRNA expression of profibrotic and inflammation-related genes
The mRNA expression of profibrotic and inflammation-related genes (Table 1) in the renal cortical region was quantified by qPCR as previously described (Marques et al., 2016) . Briefly, complementary DNA was generated using the Applied Biosystems High Capacity cDNA
Reverse Transcription kit (Thermo Fisher Scientific, Waltham, MA, USA). Samples were amplified with SYBR Green PCR master mix and run in duplicate using the QuantStudio 7 Flex Real-Time PCR system (both from Thermo Fisher Scientific). Gapdh was used as the reference transcript.
Assessment of total plasma nitrate and nitrite concentrations
Plasma samples were centrifuged ( 
Statistical analysis
GraphPad Prism (v.7; GraphPad Software, San Diego, CA, USA) was used to perform all statistical analyses. Data are means ± SD.
The effects of serelaxin were analysed using one-way ANOVA followed by Tukey's post hoc tests for multiple comparisons. Measurements of cardiac structure and function via echocardiography were repeated in the same mouse, and these data were analysed using a two-way repeated-measures ANOVA followed by Sidak's post hoc test. Two-tailed P ≤ 0.05 was considered statistically significant.
RESULTS
Organ weights
Heart, lung and liver weights were 34, 53 and 28% greater, respectively, in vehicle-treated DCM mice compared with vehicle-treated WT mice (P ≤ 0.05; Table 2 ). Kidney weight was 17% less in vehicle-treated DCM mice compared with their WT counterparts (P = 0.02; Table 2 ). In both genotypes, serelaxin had minimal effect on heart, lung, kidney and liver weights (P ≥ 0.20; Table 2 ).
Serelaxin attenuated renal fibrosis in DCM mice
Renal tubulointerstitial and glomerular fibrosis were ∼3-fold greater in vehicle-treated DCM mice compared with vehicle-treated WT mice (P ≤ 0.001; Figure 1 ). Renal tubulointerstitial and glomerular fibrosis were less (by 46 and 45%, respectively) in DCM mice treated with serelaxin compared with those treated with vehicle (P ≤ 0.01; Figure 1 ).
Effects of serelaxin on renal function
The urinary albumin:creatinine ratio was ∼3-fold greater in vehicletreated DCM mice compared with vehicle-treated WT mice (P = 0.02; Figure 2 ). In DCM mice, serelaxin had no significant effect on urinary albumin:creatinine ratio (P = 0.38; Figure 2 ).
TA B L E 2 Organ weights after treatment with serelaxin or vehicle
WT vehicle WT serelaxin DCM vehicle DCM serelaxin
Group size 8 9 7 7
Heart weight/tibia length (mg mm −1 ) 8.0 ± 1.1 7.8 ± 0.5 10.7 ± 2.0** 10.9 ± 0.9*** Kidney weight/tibia length (mg mm −1 ) 1 0 . 8 ± 1.1 10.6 ± 1.0 9.0 ± 0.8* 8.6 ± 1.3** Lung weight/tibia length (mg mm −1 ) 8.8 ± 0.4 9.2 ± 1.0 13.5 ± 3.0** 16.1 ± 3.8*** Liver weight/tibia length (mg mm −1 ) 7 2 . 5 ± 11.9 69.8 ± 11.7 92.5 ± 8.4* 79.0 ± 16.5
Values are means ± SD. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 versus vehicle-treated WT mice. P values were derived from a one-way ANOVA followed by Tukey's post hoc test. Abbreviations/definitions: DCM, dilated cardiomyopathy; kidney weight = [(left kidney weight + right kidney weight)/2; and WT, wild-type. 
*** *** F I G U R E 1 Representative images of tubulointerstitial (a and b) and glomerular (c and d) fibrosis in WT and DCM mice treated with either serelaxin (500 g kg −1 day −1 ; 8 weeks; subcutaneous minipumps; n = 5 or 6) or vehicle (20 mM sodium acetate; pH 5.0; 0.25 l h −1 ; n = 5 or 6). Scale bars: 16 m. Blue staining indicates fibrosis. Data are means ± SD. *** P ≤ 0.001 versus vehicle-treated WT mice. ++ P ≤ 0.01 versus vehicle-treated DCM mice. P values were derived from a one-way ANOVA followed by Tukey's post hoc tests. Abbreviations: DCM, dilated cardiomyopathy; SER, serelaxin; VEH, vehicle; and WT, wild-type
Expression of genes relating to fibrosis and inflammation in the renal cortex 3.4.1 Effects of serelaxin on renal inflammation
Renal cortical mRNA expression of Tnf and Il1 was ∼4-and ∼3-fold greater respectively, in vehicle-treated DCM mice compared with vehicle-treated WT mice (P ≤ 0.05; Figure 3a ,b).
Importantly, renal cortical mRNA expression of Tnf and Il1 was 56 and 58% less, respectively, in serelaxin-treated DCM mice compared with vehicle-treated DCM control animals (P ≤ 0.05; 
Serelaxin tended to restore total plasma nitrate and nitrite concentrations
Total nitrate and nitrite concentrations were 53% less in vehicletreated DCM mice compared with vehicle-treated WT mice (P = 0.005; Figure 6 ). Although not statistically significant, total nitrate and nitrite levels were 43% greater in serelaxin-treated DCM mice compared with vehicle-treated DCM mice (P = 0.08; Figure 6 ).
Serelaxin had no effect on cardiac fibrosis
Cardiac interstitial fibrosis and perivascular fibrosis were ∼17-and ∼2-fold greater, respectively, in vehicle-treated DCM mice compared with vehicle-treated WT mice (P ≤ 0.05; Figure 7 ). In both genotypes, serelaxin had minimal effect on cardiac fibrosis (P ≥ 0.18; Figure 7 ).
Cardiovascular effects of serelaxin
At baseline, mean wall thickness and fractional shortening were 28 and 54% less, respectively, in vehicle-treated DCM mice compared with vehicle-treated WT mice (P ≤ 0.001; Table 3 ). The left ventricular end-diastolic dimension was 15% greater in vehicle-treated DCM mice compared with vehicle-treated WT mice (P = 0.03; Table 3 ). In DCM mice, treatment with serelaxin had no significant effect on cardiac structure or function (P ≥ 0.48; Table 3 ).
Mean arterial pressure and left ventricular systolic pressure were 27 and 31% less, respectively, in vehicle-treated DCM mice compared with vehicle-treated WT mice (P ≤ 0.01; Table 4 ). Left ventricular enddiastolic pressure was ∼2-fold greater in vehicle-treated DCM mice compared with vehicle-treated WT mice (P < 0.001; Table 4 ). In both genotypes, serelaxin had no significant effect on any of these parameters (P ≥ 0.06; Table 4 ).
DISCUSSION
Cardioprotective effects of serelaxin have been previously reported in HF (Lekgabe et al., 2005; Liu et al., 2016) . In the present study, 
F I G U R E 5
Renal cortical mRNA expression of fibrotic markers in WT and DCM mice treated with either serelaxin (500 g kg −1 day −1 ; 8 weeks; subcutaneous minipumps; n = 7 or 8) or vehicle (20 mM sodium acetate; pH 5.0; 0.25 l h −1 ; n = 7 or 8). Data are means ± SD. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 versus vehicle-treated WT mice. P values were derived from one-way ANOVA followed by Tukey's post hoc tests. Abbreviations: sma, alpha smooth muscle actin; Mmp2, matrix metalloproteinase-2; Mmp9, matrix metalloproteinase-9; Pai1, plasminogen activator inhibitor-1; and Tgf , transforming growth factor beta. Other abbreviations are as for Figure 1 we hypothesized that serelaxin can rescue renal function in CRS type 2 by restoring NO bioavailability and attenuating renal fibrosis and inflammation. We found that renal tubulointerstitial and glomerular fibrosis were greater in vehicle-treated DCM mice compared with vehicle-treated WT mice. This is consistent with previous studies demonstrating that tubulointerstitial fibrosis is present in renal disease associated with HF (Cruz et al., 2013; Zeisberg & Neilson, 2010) . Importantly, tubulointerstitial and glomerular fibro- Renal expression of TNF is augmented in renal failure (Therrien et al., 2012) . Of note, neutralizing the expression of TNF attenuates renal inflammation and fibrosis and the development of albuminuria in rats with renal failure (Therrien et al., 2012) . Neutralization of TNF expression in renal failure is also associated with reduced activation of nuclear factor kappa-light-chain-enhancer of activated B cells and infiltration of renal interstitial macrophages (Therrien et al., 2012) . In the present study, we found that renal expression of both TNF and IL-1 was augmented in vehicle-treated DCM mice compared with vehicletreated WT mice. Renal expression of TNF and IL-1 was less in DCM mice treated with serelaxin compared with DCM mice treated with vehicle. Taken together with previous data, our present findings suggest that antifibrotic effects of serelaxin in the kidney are likely to be has been demonstrated to prevent TNF -induced endothelial dysfunction in rat aortic endothelial cells (Dschietzig et al., 2012) . Furthermore, serelaxin has been demonstrated to reverse IL-1-induced collagen production in human dermal fibroblasts (Unemori & Amento, 1990 ). Together, these data indicate that serelaxin can reduce the expression of inflammatory markers, particularly TNF , which in turn can attenuate the progression of fibrosis.
There is evidence that reduced NO bioavailability contributes to the progression of renal injury in HF (Ito et al., 2013) . Our present data indicate that plasma nitrate and nitrite concentrations were less in vehicle-treated DCM mice compared with vehicle-treated WT mice.
Plasma nitrate and nitrite concentrations tended to be greater in serelaxin-treated DCM mice compared with those treated with vehicle. There is considerable evidence that serelaxin mediates its renoprotective effects, at least in part, via increasing NO concentrations in experimental hypertension and diabetes (Ng et al., 2017; Sasser et al., 2014; Segal et al., 2012) . Furthermore, it has been demonstrated that exogenous NO improved renal function by reducing serum concentrations of the pro-inflammatory marker TNF after abdominal aortic surgery in pigs (Lozano et al., 2005) , providing evidence that improved NO bioavailability can exert renoprotective effects by inhibiting TNFmediated inflammation.
In the present study, serelaxin attenuated renal inflammation and fibrosis in DCM mice, but this did not prevent the loss of renal function. We found that the albumin:creatinine ratio was greater in vehicletreated DCM mice than in vehicle-treated WT mice, and this ratio was not significantly different between DCM mice administered vehicle and DCM mice administered serelaxin. In this context, previous data indicate that even minimal reductions in renal fibrosis are associated with improvements in renal function in rodent models (Gilbert et al., 2012; Lee, 2003; Li et al., 2014; Mimura et al., 2010) . For example, MAP (mmHg) 83 ± 6 74 ± 20 61 ± 4** 59 ± 3** LVSP (mmHg) 106 ± 9 104 ± 12 73 ± 6*** 72 ± 4*** LVEDP (mmHg) 5.8 ± 1.0 5.7 ± 1.5 12.4 ± 1.7*** 11 ± 0.7***
Values are means ± SD. ** P ≤ 0.01, *** P ≤ 0.001 versus WT mice treated with vehicle. P values were derived from a one-way ANOVA followed by Tukey's post hoc test. Abbreviations/definitions: DCM, dilated cardiomyopathy; LVEDP, left ventricular end-diastolic pressure; LVSP, left ventricular systolic pressure; MAP, mean arterial pressure [(⅓) × (systolic pressure) + (⅔) × (diastolic pressure)]; and WT, wild-type. even minute reductions in tubulointerstitial fibrosis (∼2%) were associated with 3-fold increases in glomerular filtration rate in diabetic rats (Gilbert et al., 2012) . In the present study, we did not observe an improvement in renal function in DCM mice administered serelaxin, although these mice had 40% less renal fibrosis compared with those treated with vehicle. Our present finding that serelaxin fails to improve renal function in experimental HF is consistent with data indicating that serelaxin does not improve glomerular filtration rate in HF patients (Voors et al., 2014) .
Mean wall thickness and fractional shortening were less in vehicletreated DCM mice compared with vehicle-treated WT mice. The left ventricular systolic dimension was greater in vehicle-treated DCM mice compared with vehicle-treated WT mice. Furthermore, cardiac interstitial and perivascular fibrosis were greater in vehicle-treated DCM mice compared with vehicle-treated WT mice. Serelaxin had minimal effect on cardiac structure, function and fibrosis in DCM mice.
It might be that serelaxin failed to mitigate the deleterious effects of cardiac-specific overexpression of the Mst1 transgene in these mice. Therefore, it is important to test the cardiac effects of serelaxin in other experimental models of CRS type 2. Alternatively, serelaxin might be able to target only renal and not cardiac-related mechanisms in CRS type 2. It remains to be determined whether different molecular mechanisms are responsible for driving cardiac and renal fibrosis and dysfunction in CRS type 2. Our primary aim in the present study was to test renoprotective effects of serelaxin in the presence of established cardiac dysfunction. Therefore, we used the DCM mouse model because we found previously that these mice have advanced HF and reduced renal function (Giam et al., 2017) . We demonstrated that targeting glutathione via administration of N-acetylcysteine reduced both cardiac and renal fibrosis in DCM mice (Giam et al., 2016 (Giam et al., , 2017 . Taken together with our present findings, these data suggest that an imbalance in oxidative stress and NO bioavailability might be central in driving both cardiac and renal fibrosis in CRS type 2. This hypothesis merits further investigation in future.
We found that arterial pressure was lower in vehicle-treated DCM mice than in vehicle-treated WT mice. Serelaxin had minimal effect on arterial pressure in both genotypes, indicating that antifibrotic and anti-inflammatory effects of serelaxin are mediated independently of changes in arterial pressure. This is important, because treatments that reduce arterial pressure may lead to hypotension in HF patients with reduced ejection fraction.
In conclusion, our data provide evidence that serelaxin can reduce renal fibrosis and inflammation in the presence of established cardiac dysfunction. Accordingly, it is of interest to investigate further the renoprotective effects of serelaxin in chronic HF.
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